FY26 EBITDA margin guidance raised to 27-28%
Management raised full-year EBITDA margin guidance to 27-28% from earlier 25-26%, citing strong operational performance.
LUPIN / guidance tracker
Keep management guidance in view.
Lupin · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
FY27 EBITDA margin expected at 24-25%
For FY27, management guided EBITDA margin of 24-25%, factoring in higher R&D spend and potential product mix changes.
R&D spend to remain 7.5-8.5% of sales
R&D expenditure is expected to stay in the 7.5-8.5% range going forward, with focus on complex generics and biosimilars.
Semaglutide launch in India with first-year revenue target
Management expects semaglutide to be a ₹1,500 crore market opportunity in year one, with Lupin targeting ₹50-60 crore in first-year sales.
FY27 Revenue Growth: High Single Digit
Management expects high single-digit revenue growth in rupee terms for FY27.
FY27 EBITDA Margin: ~25%
EBITDA margin guided to around 25% for FY27, down from 29.7% in FY26, factoring in competition and higher R&D.
R&D Spend: ~8% of Sales in FY27
R&D expenditure expected to be around 8% of sales for the next fiscal year.
US Business: Sustain >$1B in FY27
US revenue expected to remain above $1 billion in FY27 despite competition, supported by new launches.